GLP-1 Agonists: Mechanisms & Outcomes

Glucagon-like peptide-1 (GLP-1) is a 30-31 amino acid incretin hormone secreted by enteroendocrine L-cells in the distal small intestine and colon in response to nutrient ingestion. The incretin effect, the observation that oral glucose stimulates far more insulin secretion than the same glucose load delivered intravenously, was documented in the 1960s, but its molecular mediators (GIP and GLP-1) were not identified until the 1980s. In healthy individuals, incretins account for 50-70% of postprandial insulin secretion, a contribution that is markedly diminished in type 2 diabetes (PMID 29364588).

GLP-1's biological effects extend far beyond insulin secretion. At the pancreatic level: GLP-1 stimulates glucose-dependent insulin secretion (crucially, only when glucose levels are elevated, dramatically reducing hypoglycemia risk), suppresses glucagon secretion from alpha cells, promotes beta cell proliferation and inhibits apoptosis (demonstrated robustly in preclinical models, more modest evidence in humans), and slows gastric emptying. At the central nervous system level: GLP-1 receptors are expressed in the hypothalamus, brainstem, and limbic system, where GLP-1 signaling reduces appetite, increases satiety, and modulates food reward circuits. This central action is the primary driver of weight loss with GLP-1 agonists, patients report reduced hunger, earlier satiety, and diminished cravings for highly palatable foods (PMID 33269530).

At the cardiovascular level: GLP-1 receptors are expressed in cardiomyocytes, vascular smooth muscle, and endothelial cells, and GLP-1 agonism has been shown to improve cardiac function, reduce blood pressure (systolic BP reduction of 2-3 mmHg typical), and reduce atherosclerotic plaque progression in preclinical models. The cardiovascular outcome trials (LEADER for liraglutide, SUSTAIN-6 for semaglutide, REWIND for dulaglutide) confirmed that GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in high-risk patients with type 2 diabetes, with a meta-analysis of seven outcome trials showing an overall 12% reduction (PMID 31422062). This cardiovascular benefit, established before the era of high-dose obesity indications, is a fundamental part of the GLP-1 agonist value proposition.

The GLP-1 receptor (GLP1R) is a Class B GPCR that primarily signals through Gαs (↑cAMP) but also engages β-arrestin pathways. It is expressed in pancreatic beta cells, alpha cells, intestinal L-cells, neurons, cardiomyocytes, kidneys, lungs, and adipose tissue. The natural ligand GLP-1(7-36)amide has a plasma half-life of only 1-2 minutes due to DPP-4 cleavage at the N-terminal His-Ala bond. This extraordinarily short half-life necessitated the engineering innovations, fatty acid conjugation, sequence modification, albumin fusion, that produced the once-daily and once-weekly GLP-1 agonists now in clinical use.